Category: Multiple Sclerosis

A music based walking app for MS?

Biogen is looking to utilise a music-based digital therapeutic to help improve the gait of multiple sclerosis patients who may have difficulty walking. Developed by MedRhythms, the prescription app aims to do more than simply connect the beat of the music with walking cadence. The US-based company has been working on sensors and rehabilitation software…

Diroximel fumarate receives positive recommendation from NICE for oral treatment of relapsing-remitting multiple sclerosis (RRMS)

Diroximel fumarate is a next generation, at-home, oral fumarate treatment, with established efficacy and well-characterised safety, for people living with relapsing-remitting multiple sclerosis (RRMS)1,2 Phase 3 data and real-world evidence (n=263, based in the US) have demonstrated that treatment with diroximel fumarate results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile3,7  The…

UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc announced on 31 March, 2022 the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UPLIZNA, showing that the medicine was safe and effective in NMOSD patients who were treated with UPLIZNA after having only one attack. These data were presented during a poster session at the American Academy…

Kesimpta®▼(ofatumumab): No increased risk of severe COVID-19 infections for adults with RRMS

•    Novartis announces that the peer-reviewed journal Neurology and Therapy1 has published new data on COVID-19 infections in people living with relapsing remitting multiple sclerosis (RRMS) treated with Kesimpta® (ofatumumab) •    A very small proportion (1.5%) of those fully vaccinated and treated with ofatumumab developed COVID-19. Despite being fully or partially vaccinated all patients with…

Data support body of evidence for ocrelizumab

Genentech, a member of the Roche Group, announced new Ocrevus® (ocrelizumab) data on 4th April 2022 that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity were presented at the…

Ublituximab trials in Multiple Sclerosis

 TG Therapeutics, Inc. announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology (#AAN2022) annual meeting, 2-7 April 2022 in Washington, USA. Highlights of the presentations are outlined below. We are pleased to present additional analyses from…

MHRA approves PONVORY® (ponesimod) for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis (RMS)

The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod (n=567) led to a 30.5 percent relative reduction in annual relapse rate (p=0.0003) vs. treatment with teriflunomide (n=566), an active comparator and established first-line oral treatment in adult patients with relapsing multiple sclerosis (RMS)1-4 The OPTIMUM trial is the first head-to-head comparison of two oral…

Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis in Scotland

The Scottish Medicines Consortium recommends Novartis’ Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS) Novartis’ Kesimpta® (ofatumumab) is the first at-home self-administered B-cell therapy recommended by the Scottish Medicines Consortium (SMC) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features 1 Scotland has…

EC approves PONVORY (ponesimod)

European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p<0.001) vs. treatment with teriflunomide, an…